Celltrion to enter clinical trials of new COVID-19 treatment
The company is studying co-administration of its two coronavirus treatments By
South Korean biosimilar maker Celltrion Inc. will launch the first-phase clinical trials of its new COVID-19 treatment candidate next month, following the development of the country s first coronavirus treatment Regkirona.
Amid the rapid spread of the highly contagious Delta variant, Celltrion has upgraded the materials for the new treatment candidate CT-P63 so that the antibodies will stick easily to the surface of the coronavirus to block its penetration into our body s cells, the company said on Wednesday.
To accelerate the development, Celltrion has already produced its specimens for clinical trials.
Peru
Indonesia
South-korea
Indonesian
South-korean
South-koreans
Korea
Prevention-agency
Daewoong-pharmaceutical-co
Ministry-of-food
Korea-united-pharm-inc
Share this article
We confirmed the safety of DWN12088 and secured grounds for establishing treatment dosage
Confirming the potential as a treatment for IPF and planning to apply for Ph.2 within 2021
2
nd ODD granted as treatment for systemic sclerosis from the US FDA
SEOUL, South Korea, May 24, 2021 /PRNewswire/ Daewoong Pharmaceutical of South Korea has announced the promising clinical results of DWN12088, which is being developed as a first-in-class Prolyl-tRNA Synthetase (PRS) inhibitor for idiopathic pulmonary fibrosis (IPF) .
Daewoong Pharmaceutical (CEO Sengho Jeon) presented the results of Phase I clinical trial of DWN12088 at American Thoracic Society (ATS2021) which was held online from May 14 to 19 (local time).
Seoul
Soult-ukpyolsi
South-korea
Australia
United-states
American
Korea
Sengho-jeon
Co-ltd
Korea-drug-development-fund
American-thoracic-society
Orphan-drug-designation